We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

80 hedge funds and large institutions have $142M invested in Synergy Pharmaceuticals, Inc Common Stock in 2014 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 35 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

119% more call options, than puts

Call options by funds: $1.55M | Put options by funds: $709K

11% more funds holding

Funds holding: 7280 (+8)

2% more capital invested

Capital invested by funds: $139M → $142M (+$3.05M)

11% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 35

Holders
80
Holders Change
+8
Holders Change %
+11.11%
% of All Funds
2.31%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
31
Reduced
35
Closed
6
Calls
$1.55M
Puts
$709K
Net Calls
+$844K
Net Calls Change
+$249K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$24M +$1.56M +278,442 +7%
State Street
2
State Street
Massachusetts
$18M +$11.4M +2,036,687 +151%
BFA
3
BlackRock Fund Advisors
California
$17.9M +$503K +89,806 +3%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$14.1M -$208K -37,151 -1%
BBA
5
Baker Bros. Advisors
New York
$9.34M -$4.97M -886,516 -34%
BIT
6
BlackRock Institutional Trust
California
$5.46M -$101K -17,948 -2%
Northern Trust
7
Northern Trust
Illinois
$5.44M -$634K -113,139 -10%
WSA
8
Wall Street Associates
California
$5.04M -$179K -31,958 -3%
Morgan Stanley
9
Morgan Stanley
New York
$4.41M +$347K +61,881 +8%
UBS AM
10
UBS AM
Illinois
$3.29M -$48.6K -8,677 -1%
Cambridge Investment Research Advisors
11
Cambridge Investment Research Advisors
Iowa
$2.34M -$145K -25,824 -6%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$2.34M +$35.7K +6,362 +1%
OAM
13
Oxford Asset Management
United Kingdom
$2.2M -$414K -73,838 -15%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$2.05M +$8.47K +1,511 +0.4%
HighTower Advisors
15
HighTower Advisors
Illinois
$1.88M +$520K +92,728 +35%
TCIM
16
TIAA CREF Investment Management
New York
$1.66M -$58.8K -10,481 -3%
TSW
17
Thompson Siegel & Walmsley
Virginia
$1.37M +$274K +48,901 +23%
BGA
18
Belmont Global Advisors
Texas
$1.33M -$19.6K -3,500 -1%
BIM
19
BlackRock Investment Management
Delaware
$1.19M -$20.3K -3,628 -2%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$1.18M +$861K +153,671 +223%
Renaissance Technologies
21
Renaissance Technologies
New York
$1.05M -$79.2K -14,130 -7%
Charles Schwab
22
Charles Schwab
California
$1.02M +$18.4K +3,282 +2%
TMC
23
Trellus Management Company
Florida
$827K -$12.2K -2,181 -1%
ProShare Advisors
24
ProShare Advisors
Maryland
$800K +$585K +104,399 +226%
California State Teachers Retirement System (CalSTRS)
25
California State Teachers Retirement System (CalSTRS)
California
$775K -$11.4K -2,042 -1%

SGYP Hedge Fund Activity: Q1 2014 in Review

80 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2014, worth a combined $142M — up 2.2% from $139M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new SGYP positions and 6 closed out — a net gain of 8 holders — while 31 added to existing stakes and 35 trimmed.

The largest buyer was State Street, adding an estimated $11.4M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.97M.

  • 80 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2014, up from 72 in Q4 2013.
  • Funds reported $142M of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2014, up 2.2% quarter-over-quarter.
  • 14 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2014 and 6 closed out, a net change of +8 holders.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2014 was State Street, an estimated $11.4M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2014 was Baker Bros. Advisors, an estimated $4.97M sold.

Based on aggregated 13F filings for Q1 2014.